Hypoxia-activated prodrug: an appealing preclinical concept yet lost in clinical translation.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

9 citing papers in PubMed.

1. AI-Radiomics Can Improve Inclusion Criteria and Clinical Trial Performance.Tomography (Ann Arbor, Mich.) · 2022
   Trial
2. Pharmacological Ascorbate Induces Transient Hypoxia Sensitizing Pancreatic Ductal Adenocarcinoma to a Hypoxia Activated Prodrug.bioRxiv : the preprint server for biology · 2024
   Article
3. Medicinal Chemistry of Drugs withJournal of medicinal chemistry · 2024
   Review
4. Hypoxia signaling in cancer: Implications for therapeutic interventions.MedComm · 2023
   Review
5. Hypoxia Imaging As a Guide for Hypoxia-Modulated and Hypoxia-Activated Therapy.Antioxidants & redox signaling · 2022
   Review
6. Design, synthesis and biological evaluations of a long-acting, hypoxia-activated prodrug of fasudil, a ROCK inhibitor, to reduce its systemic side-effects.Journal of controlled release : official journal of the Controlled Release Society · 2021
   Article
7. Hypoxia and its therapeutic possibilities in paediatric cancers.British journal of cancer · 2021
   Review
8. Immunotherapy on acid: opportunities and challenges.European journal of clinical nutrition · 2020
   Review
9. Clinical Limitations of Photon, Proton and Carbon Ion Therapy for Pancreatic Cancer.Cancers · 2020
   Review

Corrections and comments

• Comment on
  Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial.2017

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as